Amendment to Notice of Extraordinary General Meeting
Released
Released
Announcement PDF
ASX Announcement
23 December 2024
Amendment to Notice of Extraordinary General
(Special) Meeting and Explanatory Memorandum
to Stockholders
Enlitic, Inc. (ASX: ENL) (“the Company”) refers to its Notice of Extraordinary General (Special)
Meeting and Explanatory Memorandum to Stockholders dated 13 December 2024 (“Original Notice
of Meeting and Explanatory Memorandum”).
The Directors have resolved to amend the exercise price of the proposed issue of Options to each of
Michael Sistenich, Lawrence Gozlan, Lisa Pettigrew and Sergio Duchini (or their respective nominees)
as set out in Resolutions 1 – 4 of the Notice from: the closing price of CDIs on the date before the
Options are granted plus a 15% premium, to: the higher of (i) the closing price of CDIs on the date
before the Options are granted plus a 15% premium; and (ii) A$0.07.
Accordingly, the Company has released an updated version of the Notice and Explanatory
Memorandum to reflect the above amendment as attached to this announcement (“Amended
Notice of Meeting and Explanatory Memorandum”).
Securityholders should note that there is no change to the date, time and venue of the Meeting.
PROXY FORMS AND CDI VOTING INSTRUCTION FORMS
There have been no changes to the Proxy Form or CDI Voting Instruction Form despatched to
Securityholders.
Proxy Forms and CDI Voting Instruction Forms accompanying the Notice remain valid. Any Proxy
Forms and CDI Voting Instruction Forms submitted by Securityholders in accordance with the
instructions in the Notice remain valid and will be accepted by the Company and counted in relation
to the Resolutions to be voted on at the Meeting.
Securityholders who have already submitted a Proxy Form and/or a CDI Voting Instruction Form with
a direction on how to vote on the Resolutions and do not wish to change their voting instruction do
not need to take any action.
Securityholders who would like to alter their votes that have already been cast can do so by following
the instructions in the Notice and original Proxy Form and/or CDI Voting Instruction Form to submit a
revised Proxy Form and/or CDI Voting Instruction Form.
Securityholders who have not yet cast their vote may lodge their Proxy Form and/or CDI Voting
Instruction Form by following the instructions in the Notice.
Valid completed CDI Voting Instruction Forms must be received by no later than 10:00am (AEDT) on
11 January 2025 (6:00pm (U.S. Eastern Standard Time) on 10 January 2025).
Enlitic, Inc.
ARBN 672 254 027
1
Valid proxies must be received by no later than 10:00am (AEDT) on 12 January 2025 (6:00pm (U.S.
Eastern Standard Time) on 11 January 2025).
Unless otherwise defined, capitalised terms in this announcement have the meaning given to them in
the Original Notice of Meeting and Explanatory Memorandum or Explanatory Memorandum or the
Amended Notice of Meeting and Explanatory Memorandum (as the context requires).
– ENDS –
This announcement was authorised for release by the Board of Enlitic, Inc.
Enquiries
Enlitic Investor Relations
Australia:
invest_au@enlitic.com
About Enlitic
Enlitic is a software company that uses artificial intelligence to develop software products that
manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and
licences such products to healthcare providers. Enlitic’s products (including its current product
offering and product suite under development) seek to standardise, protect, integrate, and analyse
data to create the foundation of a real-world evidence platform that can improve clinical workflows,
increase efficiencies, and expand capacity. Read more at enlitic.com.
Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the
US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant
to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US
Securities and Exchange Commission. The relief was given subject to certain procedures and
conditions described in the no action letter. One of the conditions is that the issuer provides
notification of the Regulation S status of its securities in communications such as this announcement.
Enlitic, Inc.
ARBN 672 254 027
2
Enlitic, Inc.
ARBN 672 254 027
NOTICE OF EXTRAORDINARY
GENERAL (SPECIAL) MEETING AND
EXPLANATORY MEMORANDUM TO
STOCKHOLDERS
Date of Meeting
14 January 2025
Time of Meeting
10:00am (AEDT)
Place of Meeting
The Meeting will be held virtually.
Virtual Online Platform using URL: https://meetings.linkgroup.com/ENLGM25
The Company will publish a virtual meeting guide on the ASX and the Company’s website outlining
how Stockholders and CDI Holders will be able to participate in the Meeting virtually.
A Proxy Form and CDI Voting Instruction Form is enclosed or has otherwise been provided to
you (as applicable)
Please read this Notice and Explanatory Memorandum carefully and in its entirety. If Securityholders
(being Stockholders and CDI Holders) are in doubt as to how to vote, you should seek advice from
your professional advisers before voting.
All Securityholders are urged to vote their Common Stock and CDIs, whether by attending the Meeting
electronically or submitting a Proxy Form (in the case of Stockholders) or submitting a CDI Voting
Instruction Form (in the case of CDI Holders).
Foreign Ownership Restriction
Enlitic’s CDIs are issued and are traded on ASX in reliance on the safe harbour provisions of
Regulation S under the US Securities Act of 1933, as amended (Securities Act), and in accordance
with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000
given to ASX by the staff at the US Securities and Exchange Commission. The CDIs have not been,
and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the
US. The holders of Enlitic’s CDIs are unable to sell the CDIs into the US or to a US person unless the
re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging
transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.
The relief was given subject to certain procedures and conditions described in the no-action letter.
One of the conditions is that Enlitic provides notification of the Regulation S status of its securities in
communications such as this document.
1
Enlitic, Inc.
ARBN 672 254 027
NOTICE OF EXTRAORDINARY GENERAL (SPECIAL) MEETING
Notice is given that the Extraordinary General (Special) Meeting of Stockholders of Enlitic, Inc.
(ARBN 672 254 027) will be held virtually on 14 January 2025 at 10:00am (AEDT) for the
purpose of transacting the following business referred to in this Notice of Extraordinary
General (Special) Meeting.
Stockholders will be able to participate in the virtual meeting, including being able to ask
questions and vote. CDI Holders will also be able to participate in the virtual meeting, including
being able to ask questions, however CDI Holders will not have the ability to vote at the virtual
meeting. The Company will publish a virtual meeting guide on the ASX and the Company’s
website outlining how Stockholders and CDI Holders will be able to participate in the Meeting
virtually.
ASX takes no responsibility for the contents of this Notice.
AGENDA
1
Resolution 1 – Grant of Options to Michael Sistenich (or his nominee) under the 2023
Equity Incentive Plan
To consider and, if thought fit, to pass the following resolution as an ordinary resolution by the
affirmative vote of a majority of the votes cast, subject to the voting exclusion statement below:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, the Directors are
authorised to issue 23,000,000 Options under the Company’s 2023 Equity Incentive Plan for no
cash consideration, with each Option having an exercise price equal to the higher of (i) the
closing price of CDIs on the date before the Options are granted plus a 15% premium; and (ii)
A$0.07, and an expiry date of 10 years from grant, to Michael Sistenich or his nominee, on the
terms and conditions set out in the Explanatory Memorandum (including Annexures A and B to
the Explanatory Memorandum).”
Voting exclusion statement: The Company will disregard any votes cast in favour of the Resolution by or on behalf of:
(a)
Michael Sistenich (and his nominee), and other persons referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who are eligible to
participate in the employee incentive scheme in question; or
(b)
an Associate of those persons.
However, this does not apply to a vote cast in favour of the Resolution by:
(a)
a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the
proxy or attorney to vote on the Resolution in that way; or
(b)
the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction
given to the Chair to vote on the Resolution as the Chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an
Associate of a person excluded from voting, on the Resolution; and
(ii)
the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Stockholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
2
2
Resolution 2 – Grant of Options to Lawrence Gozlan (or his nominee) under the 2023
Equity Incentive Plan
To consider and, if thought fit, to pass the following resolution as an ordinary resolution by the
affirmative vote of a majority of the votes cast, subject to the voting exclusion statement below:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, the Directors are
authorised to issue 6,800,000 Options under the Company’s 2023 Equity Incentive Plan for no
cash consideration, with each Option having an exercise price equal to the higher of (i) the
closing price of CDIs on the date before the Options are granted plus a 15% premium; and (ii)
A$0.07, and an expiry date of 10 years from grant, to Lawrence Gozlan or his nominee, on the
terms and conditions set out in the Explanatory Memorandum (including Annexures A and B to
the Explanatory Memorandum).”
Voting exclusion statement: The Company will disregard any votes cast in favour of the Resolution by or on behalf of:
(a)
Lawrence Gozlan (and his nominee), and other persons referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who are eligible to
(b)
an Associate of those persons.
participate in the employee incentive scheme in question; or
However, this does not apply to a vote cast in favour of the Resolution by:
(a)
a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the
proxy or attorney to vote on the Resolution in that way; or
(b)
the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction
given to the Chair to vote on the Resolution as the Chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an
Associate of a person excluded from voting, on the Resolution; and
(ii)
the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Stockholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
3
Resolution 3 – Grant of Options to Lisa Pettigrew (or her nominee) under the 2023 Equity
Incentive Plan
To consider and, if thought fit, to pass the following resolution as an ordinary resolution by the
affirmative vote of a majority of the votes cast, subject to the voting exclusion statement below:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, the Directors are
authorised to issue 2,800,000 Options under the Company’s 2023 Equity Incentive Plan for no
cash consideration, with each Option having an exercise price equal to the higher of (i) the
closing price of CDIs on the date before the Options are granted plus a 15% premium; and (ii)
A$0.07, and an expiry date of 10 years from grant, to Lisa Pettigrew or her nominee, on the
terms and conditions set out in the Explanatory Memorandum (including Annexures A and B to
the Explanatory Memorandum).”
Voting exclusion statement: The Company will disregard any votes cast in favour of the Resolution by or on behalf of:
(a)
Lisa Pettigrew (and her nominee), and other persons referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who are eligible to
participate in the employee incentive scheme in question; or
(b)
an Associate of those persons.
However, this does not apply to a vote cast in favour of the Resolution by:
(a)
a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the
proxy or attorney to vote on the Resolution in that way; or
(b)
the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction
given to the Chair to vote on the Resolution as the Chair decides; or
3
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an
Associate of a person excluded from voting, on the Resolution; and
(ii)
the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Stockholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
4
Resolution 4 – Grant of Options to Sergio Duchini (or his nominee) under the 2023 Equity
Incentive Plan
To consider and, if thought fit, to pass the following resolution as an ordinary resolution by the
affirmative vote of a majority of the votes cast, subject to the voting exclusion statement below:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, the Directors are
authorised to issue 2,800,000 Options under the Company’s 2023 Equity Incentive Plan for no
cash consideration, with each Option having an exercise price equal to the higher of (i) the
closing price of CDIs on the date before the Options are granted plus a 15% premium; and (ii)
A$0.07, and an expiry date of 10 years from grant, to Sergio Duchini or his nominee, on the
terms and conditions set out in the Explanatory Memorandum (including Annexures A and B to
the Explanatory Memorandum).”
Voting exclusion statement: The Company will disregard any votes cast in favour of the Resolution by or on behalf of:
(a)
Sergio Duchini (and his nominee), and other persons referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who are eligible to
(b)
an Associate of those persons.
participate in the employee incentive scheme in question; or
However, this does not apply to a vote cast in favour of the Resolution by:
(a)
a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the
proxy or attorney to vote on the Resolution in that way; or
(b)
the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction
given to the Chair to vote on the Resolution as the Chair decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an
Associate of a person excluded from voting, on the Resolution; and
(ii)
the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Stockholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
Details of the definitions and abbreviations used in this Notice are set out in the Glossary to the
Explanatory Memorandum.
By order of the Board
Darren Scotti
Company Secretary
Dated: 13 December 2024
(as amended 23 December 2024)
4
Who is entitled to vote at the Meeting?
If you were a Stockholder at the Record Date, you may
vote your Common Stock at the Meeting. As of the Record
Date, there were 583,167,693 shares of Common Stock
outstanding (equivalent to 537,682,067 CDIs and
45,485,626 untransmuted shares of Common Stock), all of
which are entitled to vote with respect to the items of
business at the Meeting.
Each holder of Common Stock has one vote for each
Common Stock held at the Record Date.
Each CDI Holder is entitled to direct CDN to vote one
Common Stock for every CDI held by the CDI Holder.
What is the difference between a Stockholder of
Record and a Street Name Holder?
If you own Common Stock registered directly in your name
with the Company’s registry, Equiniti, you are considered
the Stockholder of Record with respect to those shares of
Common Stock. As a Stockholder of Record, you have the
right to grant your voting proxy directly to the Company or
to vote virtually at the Meeting.
If your shares of Common Stock are held in a stock
brokerage account or by a bank, trust or other nominee,
then the broker, bank, trust or other nominee is considered
to be the Stockholder of Record with respect to those
shares of Common Stock, while you are considered the
beneficial owner of those Common Stock. In that case,
your shares of Common Stock are said to be held in
"street name" and this Notice was forwarded to you by that
organisation. Street Name Holders generally cannot vote
their shares of Common Stock directly and must instead
instruct the broker, bank, trust or other nominee how to
vote their Common Stock using the method described
below under the heading ‘How do I vote my Common
Stock?’. Since a Street Name Holder is not the
Stockholder of Record, you may not vote your Common
Stock virtually at the Meeting unless you obtain a "legal
proxy" from the broker, bank, trustee, or nominee that
holds your Common Stock giving you the right to vote the
Common Stock at the meeting.
CDN is the Stockholder of Record for all shares of
Common Stock beneficially owned by CDI Holders. CDI
Holders are entitled to receive notice of and to attend the
Meeting virtually and may direct CDN to vote at the
Meeting by using the method described below under the
heading ‘How do I vote my CDIs?’.
Participating and voting virtually
Stockholders and CDI Holders attending the Meeting
virtually will be able to ask questions. The Company has
made provision for Stockholders who register their
attendance before the start of the meeting to also
electronically cast their votes on the proposed resolutions
at the Meeting.
Stockholders can vote by following the instructions set out
in the virtual meeting guide to be published on the ASX
and the Company’s website prior to the Meeting.
Stockholders will be able to vote, and Stockholders and
CDI Holders will be able to ask questions at the virtual
meeting. You are strongly encouraged to submit questions
to the Company prior to the Meeting (see instructions
below).
Questions at the Meeting
Please note, only Securityholders may ask questions once
they have been verified. It may not be possible to respond
to all questions. Securityholders are encouraged to submit
questions prior to the Meeting (please see below).
Submission of written questions to the Company in
advance of the Meeting
Securityholders may submit a written question to the
Company in advance of the Meeting by using the voting
link (if you have received this Notice via email) or by
completing and returning the Question Form (if you have
received this Notice by mail).
The Company asks that all pre-Meeting questions be
received by the Company no later than one week before
the date of the Meeting, being 10:00am (AEDT) on 7
January 2025 (6:00pm (U.S. Eastern Standard Time) on 6
January 2025).
How do I vote my Common Stock?
If you are a Stockholder of Record, there are two ways you
can vote at the Meeting:
(1)
by completing, signing and returning the Proxy
Form in accordance with its instructions; or
(2)
virtually by following the instructions set out in
the virtual meeting guide to be published on the
ASX and the Company’s website prior to the
Meeting.
Valid proxies must be received by no later than 10:00am
(AEDT) on 12 January 2025 (6:00pm (U.S. Eastern
Standard Time) on 11 January 2025).
If you hold your Common Stock as a Street Name Holder,
you must vote your Common Stock in the manner
prescribed by your broker, bank, trust or other nominee,
which is similar to the voting procedures for Stockholders
of Record. You will receive a voting instruction form to use
in directing the broker, bank, trust or other nominee how to
vote your Common Stock.
Please note that if you transmute your Common Stock to
CDIs following the Record Date, given you held Common
Stock at the Record Date, you will be entitled to vote as a
Stockholder at the Meeting.
Rights of CDI Holders
CDI Holders at the Record Date are entitled to receive this
Notice and to attend the Meeting virtually or any
adjournment or postponement of the Meeting but are not
entitled to vote virtually at the Meeting. Ahead of the
Meeting, CDI Holders may vote as set out below under the
heading ‘How do I vote my CDIs?’. Each CDI represents
one share of Common Stock and therefore, each CDI
Holder will be entitled to direct one vote for every CDI they
hold.
How do I vote my CDIs?
If you are a CDI Holder on the Record Date, there are two
ways you can vote at the Meeting:
(1)
instruct CDN (as the Stockholder of Record) to
vote the Common Stock underlying your CDIs
pursuant to your instructions in the CDI Voting
Instruction Form; or
(2)
inform the Company and CDN that you wish to
nominate yourself or another person to be
appointed as CDN’s proxy with respect to the
Common Stock underlying your CDIs for the
purposes of attending and voting virtually at the
Meeting by completing the CDI Voting
Instruction Form.
Valid completed CDI Voting Instruction Forms must be
received by no later than 10:00am (AEDT) on 11 January
2025 (6:00pm (U.S. Eastern Standard Time) on 10
January 2025).
Please note that if you transmute your CDIs to Common
Stock following the Record Date, you will need to instruct
CDN (as Stockholder at the Record Date) to vote your
CDIs and given you did not hold Common Stock as at the
Record Date, you will not be entitled to vote at the
Meeting.
What does it mean if I receive more than one set of
proxy materials?
If you receive more than one set of proxy materials, it
means that you hold Common Stock and/or CDIs
registered in more than one account. To ensure that all of
your Common Stock and/or CDIs are voted, please submit
proxies and/or voting instructions (as applicable) for all of
your Common Stock and/or CDIs.
6
Enlitic, Inc.
ARBN (672 254 027)
EXPLANATORY MEMORANDUM
This Explanatory Memorandum is intended to provide Securityholders with sufficient information to
assess the merits of the Resolutions contained in the accompanying Notice of Extraordinary General
(Special) Meeting of the Company.
Certain abbreviations and other defined terms are used throughout this Explanatory Memorandum.
Defined terms are generally identifiable by the use of an upper case first letter. Details of the
definitions and abbreviations are set out in the Glossary to the Explanatory Memorandum.
1
Resolution 1 – Grant of Options to Michael Sistenich (or his nominee) under 2023 Equity
Incentive Plan
The Company proposes to grant 23,000,000 Options (each with an exercise price equal to the higher
of (i) the closing price of CDIs on the date before the Options are granted with a 15% premium; and
(ii) A$0.07, and an expiry date of 10 years from grant) under the Company’s 2023 Equity Incentive
Plan to Michael Sistenich, or his nominee.
The Company is at its early stages of development and has financial restrictions on it. The Directors
(in the absence of Michael Sistenich) consider that the grant of Options represents a cost-effective
way for the Company to remunerate and incentivise Michael Sistenich, as opposed to additional cash
remuneration.
The number of Options to be granted to Michael Sistenich, or his nominee has been determined
based upon a consideration of:
(a)
the remuneration of the Directors and the Company’s executives;
(b)
the extensive experience and reputation of Michael Sistenich within the healthcare industry;
(c)
the current trading price of CDIs;
(d)
the Directors’ wish to ensure that the remuneration offered is competitive with market standards
or/and practice. The Directors (in the absence of Michael Sistenich) have considered the
proposed number of Options to be granted and will ensure that Michael Sistenich’s overall
remuneration is in line with market practice;
(e)
attracting and retaining suitably qualified executives; and
(f)
incentives to attract and ensure continuity of service of Directors and executives who have
appropriate knowledge and expertise, while maintaining the Company’s cash reserves. The
Company does not consider that there are any significant opportunity costs to the Company or
benefits foregone by the Company in issuing the Options upon the terms proposed.
Valuation of Options
The indicative valuation of US$0.0127 per Option is a theoretical valuation of each Option using the
Black – Scholes methodology
The Company has valued the Options proposed to be granted to Michael Sistenich, or his nominee
using the Black – Scholes Model. The value of an option or right calculated by the Black – Scholes
Model is a function of a number of variables. The valuation of the Options has been prepared using
the following assumptions:
7
(a)
the underlying value of each share of Common Stock in the Company is based on the ASX
closing price of CDIs of A$0.075 on 6 December 2024;
(b)
the AUD:USD conversion rate of 1.5647 as at 6 December 2024 [Source: Bloomberg];
(c)
risk free rate of return – 4.25% (estimated, based on the US 10-year Treasury Rate); and
(d)
a volatility of 14.17% as determined using the 12-month volatility rate of the ASX Healthcare
Sector. The Company has determined that this volatility rate, rather than a rate determined
from the daily movements in CDI price since the Company’s listing on the ASX, is a more
reflective measure of volatility for the purposes of this valuation given the Company’s CDIs
have traded on ASX for less than 12 months.
Any change in the variables applied in the Black – Scholes calculation between the date of the
valuation and the date the Options are granted would have an impact on their value.
Information Requirements – Listing Rules 10.14 and 10.15
Listing Rule 10.14 provides that the Company must not permit any of the following persons to acquire
Equity Securities under an employee incentive scheme:
a director of the Company (Listing Rule 10.14.1);
an Associate of a director of the Company (Listing Rule 10.14.2); or
a person whose relationship with the Company or a person referred to in Listing Rule 10.14.1
or 10.14.2 is such that, in ASX’s opinion, the acquisition should be approved by its
Stockholders (Listing Rule 10.14.3),
unless it obtains the approval of its Stockholders.
The proposed grant of Options to Michael Sistenich or his nominee pursuant to the Resolution falls
within Listing Rule 10.14.1 and therefore requires the approval of Stockholders under Listing Rule
10.14.
If this Resolution is passed, the Company will grant Options to Michael Sistenich or his nominee as
noted above.
If this Resolution is not passed, the Company will not grant Options to Michael Sistenich or his
nominee and the Company may need to consider alternative ways to remunerate Michael Sistenich,
including by the payment of cash.
The following further information is provided to Securityholders for the purposes of Listing Rule 10.15:
(a)
the Options will be granted to Michael Sistenich (or his nominee);
(b)
Michael Sistenich is a Director of the Company and therefore falls within Listing Rule 10.14.1;
(c)
23,000,000 Options will be granted to Michael Sistenich (or his nominee);
(d)
the issue the subject of this Resolution is intended to remunerate or incentivise Michael
Sistenich, whose current total remuneration package is US$334,500;
(e)
no Equity Securities have previously been issued to Michael Sistenich (or his nominee) under
the Plan (for completeness, 5,280,136 Equity Securities have previously been issued to
Michael Sistenich (or his nominee) under the 2014 Equity Incentive Plan);
8
(f)
the material terms and conditions of the Options are set out in Annexure B to this Explanatory
Memorandum;
(g)
the issuing of Options will assist with aligning the interests of Michael Sistenich with the
interests of Stockholders and the longer-term performance of the Company. The Company also
believes that the grant of Options provides a cost-effective and efficient incentive (for example,
as opposed to an increased cash remuneration). The Options do not provide the allottee with
the full benefits of Common Stock ownership (such as dividend and voting rights) unless and
until su
Share your feedback
Discover